光庫科技(300620.SZ):2021年度淨利預增110%-140%
格隆匯1月17日丨光庫科技(300620.SZ)披露2021年度業績預吿,預計2021年度實現歸屬於上市公司股東的淨利潤1.24億元-1.42億元,同比增長110%-140%;預計2021年度實現歸屬於上市公司股東的扣除非經常性損益後的淨利潤1.05億元-1.18億元,同比增長129%–159%。
業績預增原因系:1、2021年公司通過技術創新、推出新產品、積極開發國內外新客户,營業收入實現穩步增長。報吿期內歸屬於上市公司股東的淨利潤較上年同期大幅增長,主要是報吿期內公司營業收入增長、全資子公司光庫米蘭有限責任公司扭虧為盈所致。2、報吿期內,預計非經常性損益對淨利潤的影響金額約為2193萬元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.